Paradigm Biopharmaceuticals Limited
PBIGF
$0.2083
$0.00633.12%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -3.57% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.57% | -- | |||
| Cost of Revenue | -3.17% | 110.00% | |||
| Gross Profit | 0.00% | 76.67% | |||
| SG&A Expenses | -2.75% | -20.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.75% | -56.76% | |||
| Operating Income | 2.75% | 56.87% | |||
| Income Before Tax | 2.75% | 37.87% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.75% | 37.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.75% | 37.87% | |||
| EBIT | 2.75% | 56.87% | |||
| EBITDA | 2.75% | 57.15% | |||
| EPS Basic | 1.79% | 49.55% | |||
| Normalized Basic EPS | 2.86% | 50.00% | |||
| EPS Diluted | 1.79% | 49.55% | |||
| Normalized Diluted EPS | 2.86% | 50.00% | |||
| Average Basic Shares Outstanding | 0.00% | 23.46% | |||
| Average Diluted Shares Outstanding | 0.00% | 23.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||